Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402740 · ClinicalTrials.gov registry record · NA
Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 322
- Enrollment target
NCT00402740 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 322 participants.
The verdict
NCT00402740, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 322 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and efficacy of the Xact™ Rapid Exchange Carotid Stent System used in conjunction with the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5) and the Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3), in the treatment of atherosclerotic carotid artery disease in high-surgical risk subjects.
Interventions
- DEVICE Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402740
The ClinicalTrials.gov registry entry for NCT00402740 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3) is the first listed.
NCT00402740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00402740 about?
NCT00402740 is a clinical study titled "Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)". The purpose of this study is to evaluate the long-term safety and efficacy of the Xact™ Rapid Exchange Carotid Stent System used in conjunction with the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5) and the Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Gen...
What is the current status of trial NCT00402740?
This trial is currently completed. It is a NA study. The enrollment target is 322 participants. The study started on 2006-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00402740?
The interventions under investigation include: Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3) (DEVICE).
Who is sponsoring clinical trial NCT00402740?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.